{"pmid":32139890,"title":"Author Correction: China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response.","text":["Author Correction: China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response.","An amendment to this paper has been published and can be accessed via a link at the top of the paper.","Nat Med","Nkengasong, John","32139890"],"abstract":["An amendment to this paper has been published and can be accessed via a link at the top of the paper."],"journal":"Nat Med","authors":["Nkengasong, John"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32139890","week":"202010|Mar 02 - Mar 08","doi":"10.1038/s41591-020-0816-5","link_erratum_for":"31988464","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647737511937,"score":6.7365713,"similar":[{"pmid":31988464,"title":"China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response.","text":["China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response.","Nat Med","Nkengasong, John","31988464"],"journal":"Nat Med","authors":["Nkengasong, John"],"date":"2020-01-29T11:00:00Z","year":2020,"_id":"31988464","week":"20205|Jan 27 - Feb 02","doi":"10.1038/s41591-020-0771-1","link_erratum_in":"32139890","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647178620930,"score":138.58607},{"pmid":32127125,"title":"Authors' response: Plenty of coronaviruses but no SARS-CoV-2.","text":["Authors' response: Plenty of coronaviruses but no SARS-CoV-2.","Euro Surveill","Reusken, Chantal B","Haagmans, Bart","Meijer, Adam","Corman, Victor M","Papa, Anna","Charrel, Remi","Drosten, Christian","Koopmans, Marion","32127125"],"journal":"Euro Surveill","authors":["Reusken, Chantal B","Haagmans, Bart","Meijer, Adam","Corman, Victor M","Papa, Anna","Charrel, Remi","Drosten, Christian","Koopmans, Marion"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32127125","week":"202010|Mar 02 - Mar 08","doi":"10.2807/1560-7917.ES.2020.25.8.2000197","keywords":["Coronavirus","SARS-CoV-2","respiratory infections"],"source":"PubMed","topics":["General Info"],"weight":1,"_version_":1661359647668305920,"score":53.77382},{"pmid":32093211,"title":"Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","text":["Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible.","J Clin Med","Deng, Sheng-Qun","Peng, Hong-Juan","32093211"],"abstract":["In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible."],"journal":"J Clin Med","authors":["Deng, Sheng-Qun","Peng, Hong-Juan"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32093211","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9020575","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","clinical characteristics","coronavirus","diagnosis","pneumonia","prevention and control","public health","treatment"],"source":"PubMed","locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647438667776,"score":44.88246}]}